Short-term clinical evaluation of β₂-microglobulin adsorbing Lixelle column S-25

-A multi-center study-

Abstract

We investigated the efficacy of reducing the serum β₂-microglobulin (β₂M) level with a single treatment of the newly developed β₂M-adsorbing column Lixell S-25 for patients with dialysis-related amyloidosis (male : 42, female : 41), as well as the incidence of adverse events. The dialysers used in the combination were of four types ; type III : 10.2%, type IV : 68.0%, type V : 20.5%, and others : 1.3%. After dialysis was performed with the Lixell S-25 column, the β₂M level was decreased significantly from 25.5mg/L to 7.5mg/L (71% of the baseline value). In addition, six patients were treated in a crossover fashion, in the first period, using S-35 and in the second using S-25. This sequence of treatment yielded β₂M clearances of 84.3mL/min and 78.0mL/min, respectively. Adverse events occurred in 8/83 patients (9.6%), and the major adverse event was hypotension. In two patients treated with the S-15, there was no hypotension while hypotension did occur when the S-25 was used. In conclusion, the S-25 exhibited a high rate of β₂M reduction, comparable to the S-35. The frequency of adverse events on short-term observation was less than that with the S-35, and similar to that with the S-15.